A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Pfizer
OHSU Knight Cancer Institute
Kestrel Therapeutics, Inc.
National Cancer Institute (NCI)
Revolution Medicines, Inc.
Seagen Inc.
Jonsson Comprehensive Cancer Center
Medical College of Wisconsin
Pfizer
Accent Therapeutics
City of Hope Medical Center
City of Hope Medical Center